|
|
|
|
Overviews
Highly Effective Reduction of C-Reactive Protein in Patients
with Coronary Heart Disease by Extracorporeal Low-Density Lipoprotein Apheresis
Wieland E, Schettler
V, Armstrong VW.
Atherosclerosis. 2002;162:187-191.
Low-Density Lipoprotein Apheresis in the Treatment of Atherosclerosis
and Other Potential Uses
Moriarty PM, Gibson CA.
Curr Atheroscler Rep. 2001;3:156-162.
Effect of HELP-LDL-Apheresis on Outcomes in Patients With
Advanced Coronary Atherosclerosis and Severe Hypercholesterolemia
Park J-W, Merz M, Braun P.
Atherosclerosis. 1998;139:401-409.
HELP Apheresis in the Treatment of Sepsis
Samtleben W, Bengsch S, Boos KS, Seidel D.
Artif Organs. 1998;22:43-46.
Safety and Effectiveness of Long-Term LDL-Apheresis in
Patients at High Risk
Thiery J, Seidel D.
Curr Opinion Lipidol. 1998;9:521-526.
Abstracts
The Efficacy and Safety of the New Heparin-Induced
Extracorporeal Low-Density Lipoprotein Precipitation System (Plasmat Futura) in
Comparison With the Currently Used System (Plasmat Secura)
Blessing F, Wang Y, Nagel D, Seidel D.
Ther Apher Dial. 2004;8:33-38.
This study examined whether the heparin-induced apheresis system, Plasmat Futura,
was comparable to the Plasmat Secura system in efficiently removing atherogenic
components, among other criteria, including clinical safety. Results demonstrate
that the Plasmat Futura system is easy to use, displays no adverse events, and is
comparable to Plasmat Secura in its ability to remove proatherogenic plasma factors.
Click for full abstract.
Long-Term Prevention of Premature Coronary Athero
sclerosis in Homozygous Familial Hypercholesterolemia
Jaeger BR, Tsobanelis T, Bengel F, Schwaiger S, Seidel D.
J Pediatr . 2002;141:125-128.
This case study of a 22-year-old woman with homozygous familial hypercholesterolemia
demonstrates the safety and efficacy of combined statins and LDL-apheresis using
the heparin-induced method.
Click for full abstract.
Evidence for Maximal Treatment of Atherosclerosis: Drastic Reduction of Cholesterol
and Fibrinogen Restores Vascular Homeostasis
Jaeger BR.
Ther Apher. 2001;5:207-211.
This article summarized the clinical and biochemical evidence for maximal treatment
of atherosclerosis by a simultaneous 60% to 70% reduction of plasma LDL cholesterol,
fibrinogen, and lipoprotein a (LPa) concentrations with statins and LDL-apheresis
using the heparin-induced method. Potential future applications are also discussed.
Click for full abstract.
Consistent Lowering of Clotting Factors for the Treatment of Acute Cardiovascular
Syndromes and Hypercoagulability: A Different Pathophysiological Approach
Jaeger BR, Goehring P, Schirmer J, et al.
Ther Apher. 2001;5:252-259.
The use of the heparin-induced method of LDL-apheresis in patients with acute cardiovascular
syndromes makes a controlled, immediately effective reduction of clotting factors
possible and induces subsequent positive effects on plasma viscosity, erythrocyte
aggregation, and microcirculation.
Click for full abstract.
Lipid Reductions by Low-Density Lipoprotein Apheresis:
A Comparison of Three Systems
Jovin IS, Taborski U, Stehr A, Müller-Berghaus G.
Metabolism. 2000;49:1431-1433.
The three commercially available systems for LDL-apheresis are compared based on
methods and efficacy. Among the three systems, immunoadsorption caused the greatest
percent reduction in LDL-C, while the heparin-induced method most efficiently eliminated
LDL-C from the plasma.
Click for full abstract.
Therapeutic Effects of LDL Apheresis in the Prevention of Atherosclerosis
Kajinami K, Mabuchi H.
Curr Opin Lipidol. 1999;10:401-406.
The efficacy and safety of LDL-apheresis has already been established for lipid
lowering in patients with refractory hypercholesterolemia. Two reports described
excellent long-term follow-up results for patient with coronary artery disease who
had been treated with LDL-apheresis using dextran sulfate cellulose columns plus
lipid-lowering therapy.
Click for full abstract.
Clinical Utility of LDL-Apheresis in the Treatment of Sudden Hearing Loss: A
Prospective, Randomized Study
Suckfüll M, Thiery J, Schorn K, Kastenbauer E, Seidel D.
Acta Otolaryngol. 1999;119:763-766.
This study sought to assess the effect of LDL-apheresis via the heparin-induced
method in removing LDL-cholesterol, fibrinogen, and lipoprotein (a) from the plasma
in patients with sudden hearing loss. Compared with standard therapy, the heparin-induced
method significantly reduced LDL-cholesterol, fibrinogen, and lipoprotein (a).
Click for full abstract.
Long-term Efficacy of Low-Density Lipoprotein Apheresis on Coronary Heart Disease
in Familial Hypercholesterolemia
Mabuchi H, Koizumi J, Shimizu M, et al, for the Hokuriku-FH-LDL-Apheresis
Study Group.
Am J Cardiol. 1998;82:1489-1495.
This study describes the 6-year safety and efficacy of intensive cholesterol-lowering
therapies with LDL-apheresis in heterozygous FH patients with CHD. Patients were
treated with lipid-lowering drugs alone or with combined drug therapy and LDL-apheresis.
Both treatment groups had significant reduction in cholesterol levels.
Click for full abstract.
Heparin-Induced Extracorporeal Fibrinogen/LDL Precipitation (HELP): A Promising
Regimen for the Treatment of Vascular Diseases
Walzl M, Walzl B, Haas A.
Angiology. 1997;48:1031-1036.
Risk factors, such as elevated fibrinogen levels and lipoproteins, contribute to
the development of atherosclerotic disease and to the deterioration of the hemorrheological,
which reduces perfusion. LDL-apheresis therapy via the heparin-induced method ensures
a safe and quick return of risk factors, yielding substantial improvement of the
microcirculation.
Click for full abstract.
HELP for the Treatment of Different Atherosclerotic Diseases
Walzl M, Walzl B, and the HELP Study Group.
Jpn J Apheresis. 1997;16:237-238.
The authors review various diseases in which LDL-apheresis therapy via the heparin-induced
method may be applied, including cerebrovascular disease and ocular microcirculatory
disorders.
Full abstract not available.
Additional Citations
HELP Apheresis Therapy in the Treatment of Severe Hypercholesterolemia: 10 Years
of Clinical Experience
Seidel D.
Artif Organs. 1996;20:303-310.
Click for full abstract.
Efficacy of Lipid Apheresis: Definitions and Influencing Factors
Bosch T, Seidel D, Gurland HJ.
Int J Artif Organs. 1995;18:210-215.
Click for full abstract.
Regression of Transplant Coronary Artery Disease During Chronic HELP Therapy:
A Case Study
Park J-W, Vermeltfoort M, Braun P, May E, Merz M.
Atherosclerosis. 1995;115:1-8.
Click for full abstract.
Lack of Plasma Lipid Peroxidation During LDL-Apheresis by Heparin-Induced Extracorporeal
LDL-Precipitation
Wieland E, Schettler V, Creutzfeldt C, Kickbusch H, Schuff-Werner P.
Eur J Clin Invest. 1995;25:838-842.
Click for full abstract.
Advances in LDL-Apheresis for the Treatment of Severe Hypercholesterolemia
Gordon BR, Saal SD.
Curr Opin Lipidol. 1994;5:69-73.
Click for full abstract.
Assessment of Currently Available Low-Density Lipoprotein Apheresis Systems
Matsuda Y, Malchesky PS, Nose Y.
Artif Organs. 1994;18:93-99.
Click for full abstract.
Extracorporeal Fibrinogen and Platelet Precipitation as a New Haemorheological
Treatment for Acute Stroke
Walzl B, Walzl M, Lechner H.
J Neurol Sci. 1994;126:25-29.
Click for full abstract.
Long-Term Efficiency, Biocompatibility, and Clinical Safety of Combined Simultaneous
LDL-Apheresis and Haemodialysis in Patients With Hypercholesterolaemia and End-Stage
Renal Failure
Bosch TH, Thiery J, Gurland HJ, Seidel D.
Nephrol Dial Transplant. 1993;8:1350-1358.
Click for full abstract.
Weekly Treatment of Diet/Drug-Resistant Hypercholesterolemia With the Heparin-Induced
Extracorporeal Low-Density Lipoprotein Precipitation (HELP) System by Selective
Plasma Low-Density Lipoprotein Removal
Lane DM, McConathy WJ, Laughlin LO, et al.
Am J Cardiol. 1993;71:816-822.
Click for full abstract.
Recent Developments in Low-Density Lipoprotein Apheresis
Demant T, Seidel D.
Curr Opin Lipidol. 1992;3:43-48.
Full abstract not available.
Complement Activation and Depletion During LDL-Apheresis by Heparin-Induced
Extracorporeal LDL-Precipitation (HELP)
Würzner R, Schuff-Werner P, Franzke A, et al.
Eur J Clin Invest. 1991;21:288-294.
Click for full abstract.
BACK TO TOP
|
 |
 |
|
